Thailand Liver Cancer Therapeutics Market Report 2022 to 2030

Thailand Liver Cancer Therapeutics Market Analysis

$ 3999

By 2030, it is anticipated that the Thailand Liver Cancer Therapeutics market will reach a value of $13.2 Mn from $3.52 Mn in 2022, growing at a CAGR of 17.9% during 2022-2030. Liver Cancer Therapeutics in Thailand is dominated by a few domestic pharmaceutical companies such as Siam Bioscience, Mega Lifesciences and Bangkok Hospital. The Liver Cancer Therapeutics market in Thailand is segmented into different types of cancer and different therapy type. Some of the major factors affecting the Thailand Liver Cancer Therapeutics market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.

ID: IN10THPH039 CATEGORY: Pharmaceuticals GEOGRAPHY: Thailand AUTHOR: Dr. Vishwa Modhia

Buy Now

Thailand Liver Cancer Therapeutics Analysis Summary

By 2030, it is anticipated that the Thailand Liver Cancer Therapeutics market will reach a value of $13.2 Mn from $3.52 Mn in 2022, growing at a CAGR of 17.9% during 2022-2030.

Thailand is an upper middle-income developing country located in Southeastern Asia bordering the Andaman Sea and the Gulf of Thailand. According to the most recent WHO data, 23,883 people died from liver cancer in Thailand in 2020, accounting for 5.37 % of all deaths. Thailand ranks eighth in the world with an age-adjusted death rate of 23.18 per 100,000 inhabitants.

In Thailand, liver cancer is one of the top causes of cancer-related deaths. According to the Global Cancer Observatory, there will be 17,645 new instances of liver cancer in Thailand in 2020, with the rate anticipated to grow further. Thailand's government spent 4.4 % of its GDP on healthcare in 2020.

Thailand Liver Cancer Therapeutics Analysis

Market Dynamics

Market Growth Drivers Analysis

The Thai population is quickly ageing, which is contributing to an increase in the incidence of liver cancer. The risk of acquiring liver cancer rises with age. In Thailand, public health campaigns and educational initiatives have contributed to promoting awareness about liver cancer. This greater awareness has resulted in an increase in the number of persons seeking medical treatment for liver cancer, which has boosted the demand for liver cancer therapies. Thailand is a regional centre due to its long coastlines and proximity to rapidly rising Asian markets. These aspects could boost Thailand's Liver Cancer Therapeutics market.

Market Restraints

Patients with liver cancer may encounter stigma and prejudice in some situations due to the disease's link with drunkenness or other socially unacceptable activities in Thailand. Therapeutics for liver cancer can be costly, especially newer treatments such targeted medicines and immunotherapies. The high expense of treatment may prevent some patients from accessing these therapies, particularly those with modest incomes or without adequate health insurance. Thailand's high image of corruption and large informal sector pose a risk to businesses. These factors may deter new entrants into the Thailand Liver Cancer Therapeutics market.

Competitive Landscape

Key Players

Siam Bioscience: Siam Bioscience is a Thai biotechnology company that produces and distributes liver cancer drugs. The company focuses on developing biologics and biosimilars for cancer treatment, including liver cancer
Mega Lifesciences: Mega Lifesciences is a Thai pharmaceutical company that develops and distributes a range of liver cancer drugs. The company has a strong presence in Thailand and several other Asian countries
Green Cross Labcell: Green Cross Labcell is a Thai biopharmaceutical company that develops and distributes liver cancer drugs. The company focuses on developing targeted therapies and immunotherapies for cancer treatment
Bangkok Hospital: Bangkok Hospital is a private hospital in Thailand that provides liver cancer treatment services
Siriraj Hospital: Siriraj Hospital is a public hospital in Bangkok that offers liver cancer treatment services

Healthcare Policies and Reimbursement Scenarios

The Food and Drug Administration (FDA) and the National Health Security Office (NHSO) regulate and reimburse liver cancer therapies in Thailand, respectively. The NHSO is in charge of Thailand's universal healthcare system, which serves about 48 Mn people. Patients with liver cancer may be eligible for reimbursement for medical expenses, including the cost of therapies, under this system if their medications are on the National List of Essential Medicines (NLEM). The NLEM is a three-year-old list of medications and medical equipment that have been judged necessary for the treatment of common health disorders.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Liver Cancer Therapeutics Segmentation

By Type (Revenue, USD Billion):

Hepatocellular Carcinoma
Cholangio Carcinoma
Hepatoblastoma
Other Types

By Treatment (Revenue, USD Billion):

Chemotherapy
Immunotherapy
Targeted Therapy
Radiation Therapy
Ablation Therapy
Embolization Therapy

By Equipment (Revenue, USD Billion):

Computed Radiography
MRI
Sonography
Others

By Route of Administration (Revenue, USD Billion):

Oral
Intravenous

By End User (Revenue, USD Billion):

Hospitals
Clinics
Ambulatory Surgical Centers

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.